<DOC>
	<DOC>NCT02667587</DOC>
	<brief_summary>The purpose of this study is to evaluate patients with glioblastoma that is MGMT-methylated (the MGMT gene is altered by a chemical change). Patients will receive temozolomide plus radiation therapy. They will be compared to patients receiving Nivolumab in addition to temozolomide plus radiation therapy.</brief_summary>
	<brief_title>An Investigational Immuno-therapy Study of Temozolomide Plus Radiation Therapy With Nivolumab or Placebo, for Newly Diagnosed Patients With Glioblastoma (GBM, a Malignant Brain Cancer)</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BristolMyers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Males and Females, age ≥ 18 years old Newly diagnosed brain cancer or tumor called glioblastoma or GBM Karnofsky performance status of ≥ 70 (able to take care of self) Substantial recovery from surgery resection Tumor test result shows MGMT methylated or indeterminate tumor subtype Biopsyonly of GBM with less than 20% of tumor removed Prior treatment for GBM (other than surgical resection) Any known tumor outside of the brain Recurrent or secondary GBM Active known or suspected autoimmune disease Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>